Regeneus IPO nets $10.5m
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Stem cell firm Regeneus (RGS) will float its shares on the Australian Securities Exchange early next week after its initial public offering closed fully subscribed today.
The offer raised $10.5 million at 25 cents a share, slightly higher than its target for $10 million but below the maximum of $12 million Regeneus had allowed for depending on demand.
This puts the company’s market capitalisation at around $46 million.
Shares in the company will commence trading on the Australian Securities Exchange on September 17, marking the first non-device biotechnology float in more than two years. Regeneus had originally planned to float today, but had to wait for cheques to clear.
“We are now well-positioned to pursue our business milestones for the next two years,” executive chairman John Martin said.
In its prospectus, Regeneus said the funds were to be used primarily to fund the registration of Regeneus' CryoShot product in the US and Australia so that it can be approved for veterinary use and to develop more labs and day surgeries for its HiQCell therapy.
CryoShot is a product using donor cells for the treatment of muscoloskeletal conditions in dogs and horses, while the HiQCell therapy uses the patients' own regenerative cells from their fat tissue to treat osteoarthritis and other inflammatory conditions in humans.
Regeneus’s successful raising is a good signal for Australia’s biotech sector given the company is in the very early stages of the clinical process.
Call 1300 880 160
Start a chat
Schedule a call
